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ABSTRACT
Background: Vitamin D has been suggested to
inﬂuence the incidence and prognosis of breast cancer,
and studies have found better overall survival (OS)
after diagnosis for breast cancer in summereautumn,
where the vitamin D level are expected to be highest.
Objective: To compare the prognostic outcome for
early breast cancer patients operated at different
seasons of the year.
Design: Open population-based cohort study.
Setting: Danish women operated 1978e2010.
Cases: 79658 adjusted for age at surgery, period of
surgery, tumour size, axillary lymph node status and
hormone receptor status.
Statistical analysis: The association between OS and
season of surgery was analysed by Cox proportional
hazards regression models, at survival periods 0e1,
0e2, 0e5 and 0e10 years after surgery. A two-sided
p value <0.05 was considered statistical signiﬁcant.
Results: Only after adjustment for prognostic factors
that may be inﬂuenced by vitamin D, 1-year survival
was close to signiﬁcantly associated season of
surgery. 2, 5 and 10 years after surgery, the
association between OS and season of surgery was not
signiﬁcant.
Limitations: Season is a surrogate measure of
vitamin D.
Conclusions: The authors found no evidence of
a seasonal variation in the survival after surgery for
early breast cancer. Lack of seasonal variation in this
study does not necessarily mean that vitamin D is of
no importance for the outcome for breast cancer
patients.
INTRODUCTION
Over the past decades, ecological studies
have inspired to the hypothesis that exposure
to sunlight and hence difference in serum
vitamin D may inﬂuence both risk and
prognosis for breast cancer.
1 2 The hypothesis
has been supported by several in vitro and
animal studies,
34in addition to caseecontrol
and cohort studies with measurements of
vitamin D as serum 25 hydroxy-vitamin D (25
(OH)D),
5e15 although not all studies
including two meta-analyses could support
these ﬁndings.
16e19 Four studies found the
prognosis of breast cancer to vary with the
season for diagnosis. The three of them
found that patients diagnosed in
summereautumn had a better disease
outcome than those diagnosed in wintere
spring,
20e22 and one study found a higher
overall mortality for patients diagnosed in
late summer compared with those diagnosed
in mid-winter.
23
In Denmark, positioned at 55e588
northern latitude, there is no sufﬁcient sun
to synthesise vitamin D in the human skin
during 6e8 months of the year. Measure-
ments of vitamin D in healthy Danish volun-
teers demonstrate a pronounced seasonal
variation of vitamin D with a maximum in
late summer and a minimum in early spring,
which indicates that the content of vitamin D
in the average Danish diet could not
compensate for the lack of sun-induced
vitamin D production during wintertime.
24
If the vitamin D status at the time of the
operation is important for the overall survival
(OS), it should be both easy and inexpensive
to adjust preoperatively. The aim of this study
is to compare the prognostic outcome for
early breast cancer patients diagnosed and
operated at different seasons of the year
based on a large population-based registra-
tion of women with breast cancer in
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ARTICLE SUMMARY
Article focus
- Breast cancer survival and season of surgery.
Key message
- No evidence of a seasonal variation.
Strengths and limitations of this study
- The sample size (approximately 80000 cases).
- The population-based approach in a limited
geographic area.
- The prospectively collected characteristics of
tumour and lymph node status.
- The long follow-up (median 10.0 years).
- The lack of information about vitamin D status in
the individual patient at the time of surgery.
- It is not known whether vitamin D levels of
the breast cancer patients follow that of the
background population.
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MATERIALS AND METHODS
The Danish Breast Cancer Cooperative Group (DBCG)
founded in 1977 is a population-based registry, which
collects data on almost all cases of invasive breast cancer
among residents in Denmark (a population of 5.5
million, emigration and immigration rates <2%)
(http://www.dst.dk). Virtually, all involved Danish
hospital departments have applied DBCG’s guidelines
for diagnostic procedures, surgery, radiotherapy, adju-
vant systemic therapy and follow-up for early breast
cancer. Diagnostic, therapeutic and follow-up data have
been accumulated prospectively in the DBCG registry by
the use of standardised forms. The DBCG Data Center
applied the same procedures for all patients, including
monitoring and analysis of data, whether or not the
patients participated in randomised trials.
25
Cases
The present analysis includes all women, who had a
completely resected invasive carcinoma of the breast and
no signs of distant metastasis as determined by routine
examinations (physical examination, clinical chemistry,
chest radiography and other examinations if indicated).
Cases with bilateral breast cancer were included
(n¼1535), and the tumour characteristics of the side
with the least favourable prognostic impact were
recorded in the DBCG registry. A negative sentinel node
biopsy or axillary clearance (levels I and II) in combi-
nation with breast-conserving surgery or mastectomy was
required. Radiotherapy to the breast was mandatory
following lumpectomy. Further description of the data-
base and treatment guidelines has been given
elsewhere.
25 26
From 1 June 1978 to 31 May 2010, 89409 cases were
registered. Of these, 3113 had a diagnosis of previous
breast cancer, other malignancy (except non-melanoma
skin tumours) or distant metastasis and 610 patients
were not operated. Further excluded from the analyses
were patients with unknown tumour size (n¼2045) and/
or unknown axillary lymph node status (n¼5678). In
total, 79658 cases were included for further analyses
(ﬁgure 1).
Variables
The seasons of surgery, generally 1e3 weeks after the
diagnosis, were deﬁned as follows: winter (1 December
to 28 or 29 February), spring (1 March to 31 May),
summer (1 June to 31 August) and autumn (1
September to 30 November), so the summer period
includes the months with the possibility of most sun
exposure due to the altitude of the sun and vacations.
Treatment periods were categorised according to the
national programmes initiated in 1977, 1982, 1989, 1999,
2001, 2004 and 2007.
25 The age at surgery was cate-
gorised in intervals: #39, 40e49, 50e59, 60e69, 70e79
and $80 years. Tumour size was categorised according to
the largest tumour diameter: 0e10, 11e20, 21e50 and
$51 mm. The spread of breast cancer to locoregional
lymph nodes was categorised as negative, one to three
positive lymph nodes and four or more positive lymph
nodes. The hormone receptor status was categorised as:
negative, oestrogen receptor or progesterone receptor
positive and unknown. The histopathological status was
categorised in ﬁve groups as: grade I, II or III ductal
carcinoma, lobular carcinoma and carcinoma of other
types or unknown diagnosis. The frequency of allocated
systemic treatment (chemotherapy and endocrine
therapy) by season of surgery was reported.
End point
OS was measured from the date of surgery to the date of
death. Observations were censored at emigration or at 1
June 2011, which was the date of data withdrawal of
patient vital status from the Danish Centralised Civil
Register.
Statistical analysis
The association between OS and season of surgery was
analysed by Cox proportional hazards regression
Invasive carcinoma of the breast,
surgery 1 June 1978 to 31 May 2010
n=89 409
Excluded
Previous mamma cancer,
n=3113
Not definitive surgery:
n=610
Study population
n=85 686
Tumour size or nodal status
missing:
n=6028
Data available for analysis:
n=79 658
previous malignancies* or
distant metastasis:
Figure 1 Flow diagram: prospective registration of Danish
women operated for early breast cancer 1978e2010. *Except
non-melanoma skin tumours.
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27 28 The effects of season of surgery were
analysed in models with an increasing level of adjust-
ment for prognostic variables: models stratiﬁed by
treatment programme (adjusted I); models stratiﬁed
by treatment programme and age at surgery (adjusted
II) and models stratiﬁed by treatment programme, age
at surgery, hormone receptor status and lymph node
status and further including the effects of tumour size
and histological type (fully adjusted). The interpreta-
tions of a seasonal effect on survival in these models
differ according to the level of adjustment. In the fully
adjusted model, the seasonal effect includes the effects
of unknown or not included prognostic variables
including the alleged effect of vitamin D. In the adjusted
II model, the seasonal effect includes the effects of both
known and unknown prognostic variables. In the
adjusted I model, the seasonal effect further includes
the effects of referral pattern, that is, patient age at
Table 1 Prognostic factors by season among 79658 Danish women operated for early breast cancer between 1 June 1978
and 31 May 2010
Characteristic
Winter Spring Summer Autumn Total
n% n% n% n% n%
Total 18760 20067 20033 20798 79658
Age at surgery*
#39 years 1051 5.6 1057 5.3 1001 5.0 1094 5.3 4203 5.3
40e49 years 3249 17.3 3604 18.0 3524 17.6 3637 17.5 14014 17.6
50e59 years 4906 26.2 5251 26.2 5232 26.1 5461 26.3 20850 26.2
60e69 years 5203 27.7 5506 27.4 5520 27.6 5702 27.4 21931 27.5
70e79 years 3233 17.2 3436 17.1 3541 17.7 3642 17.5 13852 17.4
$80 years 1118 6.0 1213 6.0 1215 6.1 1262 6.1 4808 6.0
Period of surgeryy
1977e1989 4592 24.5 4783 23.8 5115 25.5 5448 26.2 19938 25.0
1990e1999 5626 30.0 6160 30.7 6359 31.7 6559 31.5 24704 31.0
2000e2010 8542 45.5 9124 45.5 8559 42.7 8791 42.3 35016 44.0
Tumour sizez
0e10 mm 2832 15.1 3136 15.6 2972 14.8 3211 15.4 12151 15.3
11e20 mm 7419 39.5 7983 39.8 7945 39.7 8310 40.0 31657 39.7
21e50 mm 7469 39.8 7964 39.7 8053 40.2 8201 39.4 31687 39.8
>50 mm 1040 5.5 984 4.9 1063 5.3 1076 5.2 4163 5.2
Nodal statusx
Negative 9767 52.1 10672 53.2 10723 53.5 11233 54.0 42395 53.2
1e3 positive 5772 30.8 5984 29.8 5915 29.5 6015 28.9 23686 29.7
$4 positive 3221 17.2 3411 17.0 3395 16.9 3550 17.1 13577 17.0
Histological group{
Ductal grade I 4808 25.6 5129 25.6 5242 26.2 5390 25.9 20569 25.8
Ductal grade II/?** 7268 38.7 7672 38.2 7542 37.6 7893 38.0 30375 38.1
Ductal grade III 3351 17.9 3504 17.5 3517 17.6 3626 17.4 13998 17.6
Lobular 1963 10.5 2135 10.6 2086 10.4 2137 10.3 8321 10.4
Other invasive 1370 7.3 1627 8.1 1646 8.2 1752 8.4 6395 8.0
ERePgR status
Negative 2919 15.6 3176 15.8 3299 16.5 3217 15.5 12611 15.8
Positive 12453 66.4 13054 65.1 12994 64.9 13849 66.6 52350 65.7
Unknown 3388 18.1 3837 19.1 3740 18.7 3732 17.9 14697 18.5
Per cent ErePgR
positiveyy zz
81.0 80.4 79.8 81.1 80.6
Adjuvant systemic therapy
None 9449 50.4 10256 51.1 10551 52.7 10940 52.6 41196 51.7
Chemotherapyxx 4749 25.3 5063 25.2 4849 24.2 5043 24.2 19704 24.7
Endocrine therapy{{ 6270 33.4 6629 33.0 6347 31.7 6654 32.0 25900 32.5
*c
2¼12.2, df¼15, p¼0.66.
yc
2¼80.7, df¼6, p¼0.0001.
zc
2¼14.9, df¼9, p¼0.09.
xc
2¼19.5, df¼6, p¼0.003.
{c
2¼25.1, df¼12, p¼0.014.
**Unknown grade, n¼1533.
yyPositive relative to sum of positive and negative.
zzc
2¼12.7, df¼3, p¼0.005.
xxc
2¼11.7, df¼3, p¼0.009.
{{c
2¼18.4, df¼3, p¼0.0004.
ER, oestrogen receptor; PgR, progesterone receptors.
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to meet the proportional hazards assumption as assessed
by Schoenfeld residuals plots.
27 The analyses were done
for four survival periods: 0e1, 0e2, 0e5 and 0e10 years
after surgery. The null hypothesis of no survival effect of
season of surgery was assessed by the Wald c
2 statistic,
and a two-sided p value <0.05 was considered statistically
signiﬁcant. The HRs of season of surgery (winter as
reference level) together with their 95% CIs are
reported. Due to the long period of inclusion, the
potential heterogeneity of seasonal effects according to
period of inclusion was investigated in models including
an interaction term of season of surgery and programme
series (1977 and 1982 vs 1989 vs 1999, 2001, 2004 and
2007). Analysis was performed with SAS V.9.1 (SAS
Institute).
RESULTS
The person-years of observation were 78587 for the
survival period 0e1 years, 151980 for the survival period
0e2 years, 327646 for the survival period 0e5 years and
516011 for the survival period 0e10 years after surgery.
For the latter group, the median observation period for
patients without an event was 10.0 year. The basic char-
acteristics of the patient material according to season of
surgery are presented in table 1.
HRs of OS up to 10 years with surgery performed in
winter as reference are given in table 2. Overall, no
statistically signiﬁcant association between OS and
season of surgery are observed in 2-, 5- and 10-year
follow-up periods. Only for the 1-year follow-up, a close
to signiﬁcant association is observed (p¼0.052, fully
adjusted analysis); OS is highest for patients undergoing
surgery in autumn (HR: 0.97, 95% CI 0.86 to 1.09) and
lowest for patients undergoing surgery in summer (HR:
1.12, 95% CI 1.00 to 1.26). Heterogeneity of seasonal
effects according to period of inclusion was not statistical
signiﬁcant irrespective of model adjustment or survival
period.
DISCUSSION
In the present study, we found no evidence of a seasonal
variation in the OS among almost 80000 Danish women
with primary breast cancer. The strengths of this study
are the sample size, the population-based approach in
a limited geographic area,
29 the prospectively collected
characteristics of tumour and lymph node status and the
long follow-up (median 10.0 years). The detailed infor-
mation’s offer the possibility of including season of
surgery in a multivariate analysis with the variables year,
age at surgery, tumour size, nodal status, hormone
receptor status and histopathological type. It should be
noted that in our analysis, the ‘adjusted II’ models are
stratiﬁed by treatment programme and age at surgery
only. Thus, the estimates of association between OS and
seasonal of surgery are not affected by the variables
Table 2 Overall survival by Cox proportional hazards regression at survival periods 0e1, 0e2, 0e5 and 0e10 years
post-surgery
Period of follow-up Adjusted I* Adjusted IIy Fully adjustedz
Season of surgery HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
0e1 years after surgery
Winter 1 (reference) 0.053 1 (reference) 0.067 1 (reference) 0.052
Spring 1.07 (0.95 to 1.20) 1.06 (0.95 to 1.19) 1.07 (0.96 to 1.20)
Summer 1.09 (0.97 to 1.22) 1.08 (0.96 to 1.21) 1.12 (1.00 to 1.25)
Autumn 0.95 (0.84 to 1.06) 0.94 (0.84 to 1.06) 0.97 (0.86 to 1.09)
0e2 years after surgery
Winter 1 (reference) 0.19 1 (reference) 0.17 1 (reference) 0.43
Spring 0.99 (0.92 to 1.06) 0.98 (0.92 to 1.06) 1.00 (0.93 to 1.07)
Summer 0.99 (0.92 to 1.06) 0.99 (0.92 to 1.06) 1.01 (0.94 to 1.08)
Autumn 0.93 (0.87 to 1.00) 0.93 (0.86 to 1.00) 0.96 (0.89 to 1.03)
0e5 years after surgery
Winter 1 (reference) 0.60 1 (reference) 0.48 1 (reference) 0.96
Spring 0.98 (0.94 to 1.03) 0.98 (0.94 to 1.03) 1.00 (0.95 to 1.04)
Summer 0.98 (0.94 to 1.02) 0.97 (0.93 to 1.02) 1.00 (0.95 to 1.04)
Autumn 0.97 (0.93 to 1.01) 0.97 (0.93 to 1.01) 0.99 (0.95 to 1.03)
0e10 years after surgery
Winter 1 (reference) 0.90 1 (reference) 0.81 1 (reference) 0.92
Spring 1.00 (0.96 to 1.03) 1.00 (0.96 to 1.03) 1.01 (0.98 to 1.05)
Summer 1.00 (0.96 to 1.03) 0.99 (0.96 to 1.03) 1.01 (0.98 to 1.05)
Autumn 0.99 (0.95 to 1.02) 0.98 (0.95 to 1.02) 1.00 (0.97 to 1.04)
Estimates of season of surgery are shown among 79658 Danish women operated for breast cancer between 1 June 1978 and 31 May 2010.
*Model stratiﬁed for treatment programme.
yModel stratiﬁed for treatment programme and age at surgery.
zModel stratiﬁed for treatment programme, age at surgery, hormone receptor status and nodal status and including the effects of tumour size
and histological group.
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(tumour size, positive axillary nodes, high-grade
tumours and oestrogen receptor/progesterone receptor
status). Using this approach, the independent prog-
nostic effect of season of surgery seems to disappear. The
limitations of the study are the lack of information about
serum vitamin D in the individual patient at the time of
surgery. Using the estimated UV dose as surrogate for
vitamin D status must cause reservation, as it is not
known whether vitamin D status of the breast cancer
patients follow that of the background population. Lack
of seasonal variation in this study does not necessarily
mean that vitamin D is not important for the OS for
breast cancer patients. The serum vitamin D in Danish
women treated for breast cancer could be so low even
among patients treated in the summereautumn so that
no difference could be detected. One nested casee
control study (N¼142) showed lower serum vitamin D
among Danish patients at the diagnostic mammog-
raphy.
14 Cross-sectional studies of the plasma vitamin D
in healthy Danish volunteers demonstrate a higher level
in summereautumn than in winterespring.
24
Results from UK and Norway indicate a better prog-
nosis if diagnosis of breast cancer takes place during the
summer or autumn.
20e22 This seasonal variation was
interpreted as a result of vitamin D deﬁciency in the
dark months of the year, although one author consid-
ered the possibility that the seasonal effect might be
due to a relative higher rate of diagnoses in summer
and the prevalence of infections during wintertime
leading to early death.
20 In contrast, results from
Sweden demonstrate a worse OS for patients diagnosed
in the summer probably due to a relative reduction in
the number of early stage diagnoses from mammog-
raphy screening which are closed in the summer
months and the healthcare system treating primarily
the most sick patients in holiday periods.
23 30 Breast
cancer is regarded as a relatively slow growing cancer,
with a long preclinical course.
31 If vitamin D level
should be of etiologic or prognostic importance, it is
supposed that the inﬂuence is working over a longer
time period and not just reﬂected by vitamin D status at
time of diagnosis. If the level of vitamin D at the time of
surgery should inﬂuence prognosis, the mechanism
must be differences in perioperative resistance to
cancer dissemination and the logical precaution would
be to ensure a high preoperative vitamin D level.
However, limited evidence including the present study
supports this statement.
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